These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39093663)

  • 1. Selective Tyrosine Kinase 2 (TYK2) Inhibition in Plaque Psoriasis.
    Kircik L; Aldredge LM; DiRuggiero D
    J Drugs Dermatol; 2024 Aug; 23(8):645-652. PubMed ID: 39093663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways.
    Johnson B; Cheng L; Koenitzer J; Catlett IM; Schafer P
    Front Immunol; 2024; 15():1437512. PubMed ID: 39403378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.
    Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Takahashi K; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
    J Dermatol; 2023 May; 50(5):e138-e150. PubMed ID: 37132187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis.
    Krueger JG; McInnes IB; Blauvelt A
    J Am Acad Dermatol; 2022 Jan; 86(1):148-157. PubMed ID: 34224773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
    Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
    J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
    Roskoski R
    Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
    Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
    Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases.
    Rusiñol L; Puig L
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.
    Works MG; Yin F; Yin CC; Yiu Y; Shew K; Tran TT; Dunlap N; Lam J; Mitchell T; Reader J; Stein PL; D'Andrea A
    J Immunol; 2014 Oct; 193(7):3278-87. PubMed ID: 25156366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TYK2: an emerging therapeutic target in rheumatic disease.
    Morand E; Merola JF; Tanaka Y; Gladman D; Fleischmann R
    Nat Rev Rheumatol; 2024 Apr; 20(4):232-240. PubMed ID: 38467779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors.
    Nogueira M; Puig L; Torres T
    Drugs; 2020 Mar; 80(4):341-352. PubMed ID: 32020553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
    Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
    Front Immunol; 2022; 13():884399. PubMed ID: 35693820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise.
    Danese S; Peyrin-Biroulet L
    Inflamm Bowel Dis; 2021 Nov; 27(12):2023-2030. PubMed ID: 34089259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
    Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
    Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
    He X; Chen X; Zhang H; Xie T; Ye XY
    Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors.
    Jensen LT; Attfield KE; Feldmann M; Fugger L
    EBioMedicine; 2023 Nov; 97():104840. PubMed ID: 37863021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712.
    Breinlinger E; Van Epps S; Friedman M; Argiriadi M; Chien E; Chhor G; Cowart M; Dunstan T; Graff C; Hardee D; Herold JM; Little A; McCarthy R; Parmentier J; Perham M; Qiu W; Schrimpf M; Vargo T; Webster MP; Wu F; Bennett D; Edmunds J
    J Med Chem; 2023 Oct; 66(20):14335-14356. PubMed ID: 37823891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis.
    Page KM; Suarez-Farinas M; Suprun M; Zhang W; Garcet S; Fuentes-Duculan J; Li X; Scaramozza M; Kieras E; Banfield C; Clark JD; Fensome A; Krueger JG; Peeva E
    J Invest Dermatol; 2020 Aug; 140(8):1546-1555.e4. PubMed ID: 31972249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
    Norman P
    Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors.
    Du SS; Fang YQ; Zhang W; Rao GW
    Curr Med Chem; 2024; 31(20):2900-2920. PubMed ID: 38904160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.